Welcome to our dedicated page for PRECIGEN SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
Precigen, Inc. (PGEN) filed a Shelf Registration Statement on Form S-3 registering secondary sales by selling stockholders of up to 143,809,489 shares of Common Stock and 79,000 shares of Preferred Stock. The prospectus states all proceeds from these sales will go to the selling stockholders and the company will receive no proceeds. The registration covers a wide range of sale methods including block trades, at-the-market offerings, privately negotiated transactions, and hedging transactions.
The filing references incorporated reports and describes risks, noting purchasers may lose their entire investment. It identifies key officers and directors, and discloses concentrated beneficial ownership controlled by R.J. Kirk and affiliated entities. Legal and accounting fees related to the offering are included but cannot be estimated at this time.
Precigen, Inc. entered into a Commercial Supply Agreement with Catalent Maryland, Inc. for the commercial manufacture of PAPIZEMOS. Under the agreement, Catalent will provide services such as analytical work, development, processing, validation and product maintenance as defined in a Plan Document.
During the term of the agreement, Precigen has agreed to use Catalent exclusively for external commercial fill-and-finish manufacturing of all reported PAPIZEMOS volumes in the defined territory. If the Plan Document sets any minimum annual batch requirements, Precigen must purchase at least those amounts in the relevant contract years. Precigen will pay Catalent agreed prices and fees for these services, which are subject to annual adjustments for factors including labor, utilities and overhead, and will also pay certain maintenance fees and expenses.
The initial term runs for three years from the effective date and then renews automatically in one-year increments unless either party gives at least twelve months’ written notice before the end of the current term. The agreement may be terminated by either party for material breach or certain other specified circumstances after any applicable cure period and includes customary provisions on quality, delivery, warranties, intellectual property, confidentiality and indemnification.
Precigen, Inc. filed a current report to note that it provided a slide presentation at a webcast investor conference held on August 18, 2025 at 8:00 a.m. Eastern Time. The presentation is included as Exhibit 99.1 to the report but is furnished rather than filed for securities law purposes.
Precigen, Inc. reported condensed financials for the quarter ended June 30, 2025 showing regulatory progress for its lead gene therapy and material financial strain. The FDA granted priority review to the Biologics License Application for PRGN-2012, with a PDUFA target action date of August 27, 2025; PRGN-2012 is intended to treat adults with recurrent respiratory papillomatosis and has not been approved.
Financially, the company recorded a net loss of $80,795 (amounts in thousands, i.e., $80.8 million) for the six months ended June 30, 2025 and used $35,302 of cash in operating activities in that period. As of June 30, 2025, it held $13,760 in cash and $45,993 in short-term investments (totaling $59,753). Warrant liabilities were $78,558 and Series A preferred mezzanine equity was $30,883, while accumulated deficit totaled $2,171,501. Management concluded these conditions raise substantial doubt about the company’s ability to continue as a going concern for one year absent additional funding or approval-related revenue.
Operationally, the company realigned to a single reporting segment and previously reduced its workforce by over 20% to focus resources on PRGN-2012. The company recorded a $3,907 goodwill impairment in Q2 2025 and recognized prior noncurrent asset impairments in 2024. These items, combined with large noncash warrant fair-value movements, contribute to earnings volatility despite regulatory momentum.
Precigen COO Rutul R. Shah received a significant equity award of 180,000 Restricted Stock Units (RSUs) on June 26, 2025. The RSUs represent the right to receive an equivalent number of Precigen common stock shares upon vesting.
The vesting schedule is structured as follows:
- 50% of RSUs vest on May 23, 2026
- Remaining 50% vest in equal monthly installments over the following three years
This Form 4 filing, executed by Donald P. Lehr as attorney-in-fact on Shah's behalf, indicates a long-term retention strategy for the Chief Operating Officer. The RSUs were granted at $0 cost to the executive, representing a significant potential value tied to future company performance and share price appreciation.
Donald P. Lehr, Chief Legal Officer of Precigen (PGEN), reported receiving 125,000 Restricted Stock Units (RSUs) on June 26, 2025. Each RSU represents a contingent right to receive one share of Precigen common stock.
The RSUs follow a specific vesting schedule: 50% will vest on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years. The RSUs were granted at no cost ($0) to the executive.
This equity compensation grant aligns the legal officer's interests with shareholders through long-term vesting requirements. The transaction was reported via Form 4 within the required reporting timeframe, with the filing made on June 28, 2025.
Helen Sabzevari, President, CEO, and Director of Precigen, received a significant equity award of 500,000 Restricted Stock Units (RSUs) on June 26, 2025. This represents a substantial insider grant that aligns executive interests with shareholder value.
Key details of the RSU grant:
- Each RSU converts to one share of Precigen common stock
- Vesting schedule: 50% vests on May 23, 2026, with remaining vesting in equal monthly installments over three years
- Grant price: $0 (typical for RSU awards)
- Ownership form: Direct
This Form 4 filing indicates continued commitment to executive retention and long-term performance alignment through equity-based compensation. The extended vesting schedule suggests a focus on long-term value creation and executive retention.